oestrogen

PreclinicalSmall molecule

Novo Nordisk

oestrogen is one of 5 small molecule programs targeting Withdrawal. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

WithdrawalCompleted

WithdrawalPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Withdrawal

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Phase 2

1 2

Depacon

AbbVie

Preclinical

2 3

Nicotine Lozenge

FFertin Pharma A/S

Preclinical

1 4

oestrogen

Novo Nordisk

Preclinical

1 5

Withdrawal

MMcGill University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Turner syndrome1 trial

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT01518062·65 enrolled

Withdrawal1 trial

Oestrogen Withdrawal in Hypopituitary Women

Completed·UUniversity of Aarhus·N/A·NCT00572390·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for oestrogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — oestrogen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for oestrogen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novo Nordisk

oestrogen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Turner syndrome1 trial

Withdrawal1 trial

References

Drug Info

Quick Facts

Related News